10-Q: Rockwell Medical Reports Steep Revenue Decline, Net Loss

Rockwell Medical experienced a significant drop in net sales and shifted to a net loss for Q3 and the first nine months of 2025, primarily due to reduced DaVita purchases.

Summary

• Net sales for the three months ended September 30, 2025, decreased by 44% to $15.9 million from $28.3 million in the prior year period.
• Net sales for the nine months ended September 30, 2025, decreased by 34% to $50.9 million from $76.8 million in the prior year period.
• The company reported a net loss of $1.8 million ($0.05 per share) for Q3 2025, compared to net income of $1.7 million ($0.05 per share) for Q3 2024.
• For the nine months ended September 30, 2025, the net loss was $4.8 million ($0.14 per share), a significant decline from net income of $0.3 million ($0.01 per share) in the prior year period.
• The substantial decrease in sales is primarily attributed to a $13.0 million reduction in sales to DaVita for Q3 2025 and a $27.9 million reduction for the nine months, as DaVita transitions to another supplier.
• Rockwell Medical secured a new multi-million dollar, three-year product purchase agreement with Innovative Renal Care (IRC) in Q2 2025.
• Manufacturing at the Greer, South Carolina facility was concluded in Q3 2025 as part of streamlining efforts, incurring $0.8 million in severance and closure costs for the nine months.
• All remaining deferred license revenue related to Triferic distribution agreements was recognized, and all Triferic license agreements have been terminated, with remaining Triferic inventory written off.
• As of September 30, 2025, cash, cash equivalents, and available-for-sale investments totaled $23.7 million, with net working capital of $27.9 million.
• The company has $13.1 million remaining available under its At-The-Market (ATM) facility for potential capital raises.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a substantial decline in revenue and a shift from profitability to significant losses, primarily driven by the loss of a major customer (DaVita). While there are efforts to secure new customers and streamline operations, the immediate financial performance is concerning, and future capital raises are anticipated.

Positives

• Secured a new multi-million dollar, three-year product purchase agreement with Innovative Renal Care (IRC) in Q2 2025, with an option to extend for an additional year.
• Implemented cost containment activities and streamlined operations by concluding manufacturing at the Greer, South Carolina facility, expected to be substantially completed by December 31, 2025.
• Net working capital increased to $27.9 million as of September 30, 2025, from $22.9 million at December 31, 2024.
• Management believes the company has sufficient funds to meet its operating requirements for at least the next twelve months.
• The company is in compliance with all covenants under its Loan Agreement with Innovatus, which includes an interest-only period for 36 months and an extended maturity date to January 1, 2029.
• Realized gains on available-for-sale investments totaled $0.1 million for the three months and $0.2 million for the nine months ended September 30, 2025.
• Interest income increased to $0.055 million for the three months and $0.190 million for the nine months ended September 30, 2025.

Negatives

• Net sales decreased significantly by 44% for the three months and 34% for the nine months ended September 30, 2025, primarily due to a $27.9 million reduction in DaVita sales.
• The company reported a net loss of $1.8 million for the three months and $4.8 million for the nine months ended September 30, 2025, a substantial decline from net income in the prior year periods.
• Operating activities resulted in a net cash outflow of $3.0 million for the nine months ended September 30, 2025, a reversal from a $3.3 million inflow in the prior year.
• DaVita, a major customer, is transitioning to another supplier, leading to significantly reduced purchases and ongoing uncertainty regarding future volume commitments.
• The closure of the South Carolina manufacturing facility incurred severance and other closure-related costs of $0.5 million for the three months and $0.8 million for the nine months ended September 30, 2025.
• All Triferic license agreements have been terminated, and remaining Triferic inventory was written off, indicating the cessation of international commercialization efforts for this product.
• Research and product development expenses were immaterial due to the decision to pause all R&D related to Triferic in 2023.

Risks

• Inability to successfully negotiate a contract extension with and/or future volume commitments by DaVita, which could further impact revenue.
• Inability to secure additional capital or funding on acceptable terms, or at all, which may be required to sustain operations and execute strategic plans.
• Potential significant dilution of stockholders' interests if capital is raised through equity, which could lead to a decline in the market price of common stock.
• Limitations on incurring additional debt due to the Securities Purchase Agreement with DaVita, restricting debt to specific purposes unless DaVita consents.
• Adverse effects from the uncertain global macroeconomic environment, including changes in U.S. trade policies, instability in capital/credit markets, supply chain weaknesses, geopolitical instability, recession fears, rising interest rates, foreign exchange volatility, and inflationary pressures.
• Inability to execute on the growth strategy of the hemodialysis concentrates business and maintain sales with existing customers.
• Inability to achieve sustained profitability.
• Inability to identify, develop, in-license, or acquire new products to expand the renal care product portfolio.
• Risk of being forced to curtail all activities and ultimately cease operations if unsuccessful in executing the business plan and unable to raise required capital.
• Involvement in disputes or legal actions with contract counterparties, which could negatively impact business, results of operations, or financial condition.

Future Outlook

Management believes the company has sufficient funds to meet its operating requirements for at least the next twelve months, supported by current working capital and the ability to utilize the remaining $13.1 million under its At-The-Market (ATM) facility. The company's operational plans include executing on new customer acquisitions and cost containment. Long-term funding is highly dependent on executing the hemodialysis concentrates business growth strategy, maintaining existing customer sales, achieving sustained profitability, and identifying new products for its renal care portfolio. There is no assurance that discussions with DaVita will yield a successful outcome for future volume commitments.

Management Comments

• Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
• The Company continues to review its operational plans and execute on the acquisition of new customers, and has implemented cost containment activities.
• Rockwell's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry.
• We are an established leader in manufacturing and delivering high-quality hemodialysis concentrates and dialysates, along with certain ancillary products, to dialysis providers and distributors in the United States and abroad.
• The Company concentrates its efforts on increasing its market share, broadening its product portfolio, right-sizing its product pricing, improving gross margins, and growing the Company's business through organic and inorganic growth and other business development opportunities.

Industry Context

Rockwell Medical operates in the hemodialysis market, a critical segment for end-stage kidney disease treatment. The company is a significant supplier of concentrates in the U.S. The loss of a major customer like DaVita, a large kidney care provider, indicates intense competition and potential pricing pressures within the industry. The new agreement with Innovative Renal Care suggests the company is actively seeking to diversify its customer base and maintain market presence amidst competitive shifts. The decision to pause Triferic R&D and terminate related licenses suggests a strategic refocusing on core hemodialysis concentrate products rather than drug development.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company may be involved in routine legal proceedings from time to time, including disputes or legal actions with contract counterparties, which could negatively impact the business. However, the resolution of current pending proceedings is not expected to have a material effect on operations or consolidated financial statements.

Related Party Transactions

• DaVita, Inc. is a related party due to the issuance of Series X Preferred Stock to them on April 6, 2022.
• The company has ongoing discussions with DaVita regarding supply continuity and potential future volume commitments, despite DaVita's intention to transition to another supplier.

Stakeholder Impact

• **Shareholders**: Significant decline in net income to a net loss and potential future dilution from capital raises could negatively impact shareholder value.
• **Employees**: Closure of the South Carolina manufacturing facility resulted in severance expenses, indicating job reductions.
• **Customers**: Transition of DaVita to another supplier impacts a major customer, while a new agreement with Innovative Renal Care aims to secure new customer relationships.
• **Creditors**: The company is in compliance with all covenants under its Loan Agreement with Innovatus, which has an extended maturity date, providing some stability for creditors.
• **Suppliers**: Changes in manufacturing operations and customer base may affect supplier relationships and demand for raw materials.

Next Steps

• Continue discussions with DaVita regarding a potential contract extension and/or future volume commitments.
• Substantially complete restructuring activities associated with the Greer, South Carolina facility closure by December 31, 2025.
• Execute on the growth strategy of the hemodialysis concentrates business and maintain sales with existing customers.
• Identify, develop, in-license, or acquire new products to expand the renal care product portfolio.
• Potentially raise additional capital using the At-The-Market (ATM) facility or other financing methods, if needed.

Key Dates

Recommendation

The company faces severe headwinds, including a dramatic 44% decline in quarterly net sales and a shift from profitability to a significant net loss, primarily due to the loss of its largest customer, DaVita. While a new customer agreement was secured, it does not offset the magnitude of the DaVita revenue loss. The company is burning cash from operations and anticipates needing to raise additional capital, likely through equity, which will cause further dilution. The strategic pivot away from Triferic R&D and international licenses, while potentially streamlining, removes a future growth avenue. Given the substantial revenue contraction, negative cash flow from operations, and reliance on future capital raises in a challenging market, the stock presents a high-risk profile with significant downside potential.

Keywords

hemodialysis, dialysis concentrates, renal care, medical devices, biotechnology, healthcare, SEC filing, 10-Q, financial results, DaVita, Innovative Renal Care, RMTI